Progenics Pharmaceuticals Inc (Nasdaq: PGNX), a biopharmaceutical company, has reported its financial results for the first quarter 2009, ended 31 March 2009.
The company recorded a net loss for the quarter of USD1.8m, or USD0.06 per share (basic and diluted), compared to a net loss of USD15.5m, or USD0.52 per share, for the first quarter of 2008.
Total revenues for the first quarter 2009 were USD20.9m, compared to revenues of USD14.8m for the same period of last year.
No comments:
Post a Comment